Search research articles
Contact Us
Filters
Showing results (61-70 of 178) with videos related to
Page
of 18
Sort By:
Archives of Hematology and Blood Diseases
|
January 10, 2022
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT)
Akshata Pandit, Lai Wei, Luis Bustamante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
Hassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 27, 2007
Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor
David A Hess, Jesper Bonde, Timothy P Craft, et al.
Blood
|
October 31, 2002
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
Ravi Vij, John F DiPersio, Partha Venkatraman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2006
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
Christopher L Hallemeier, Mark D Girgis, William G Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation
Brian C Shaffer, Mahasweta Gooptu, Todd DeFor, et al.
Leukemia & Lymphoma
|
January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Alison R Walker, Hongyan Wang, Katherine Walsh, et al.
Frontiers in Immunology
|
October 7, 2022
Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program
Nosha Farhadfar, Jeni Newman, Jennifer Novakovich, et al.
Blood
|
March 6, 2002
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
Steven M Devine, Ron Hoffman, Amit Verma, et al.
Leukemia & Lymphoma
|
September 11, 2013
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
Rebecca B Klisovic, William Blum, Zhongfa Liu, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 178) with videos related to
Sort By:
Page
of 18
Archives of Hematology and Blood Diseases
|
January 10, 2022
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT)
Akshata Pandit, Lai Wei, Luis Bustamante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
Hassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 27, 2007
Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor
David A Hess, Jesper Bonde, Timothy P Craft, et al.
Blood
|
October 31, 2002
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
Ravi Vij, John F DiPersio, Partha Venkatraman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2006
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
Christopher L Hallemeier, Mark D Girgis, William G Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation
Brian C Shaffer, Mahasweta Gooptu, Todd DeFor, et al.
Leukemia & Lymphoma
|
January 20, 2016
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia
Alison R Walker, Hongyan Wang, Katherine Walsh, et al.
Frontiers in Immunology
|
October 7, 2022
Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program
Nosha Farhadfar, Jeni Newman, Jennifer Novakovich, et al.
Blood
|
March 6, 2002
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
Steven M Devine, Ron Hoffman, Amit Verma, et al.
Leukemia & Lymphoma
|
September 11, 2013
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
Rebecca B Klisovic, William Blum, Zhongfa Liu, et al.
Page
of 18